Eukaryotic translation initiation factor 4A1 (EIF4A1) is an ATP-dependent RNA helicase and a core component of the eIF4F translation initiation complex. By unwinding highly structured 5'-untranslated regions (5'-UTRs) of oncogenic mRNAs (such as MYC, BCL2, and CCND1), EIF4A1 acts as a gatekeeper for the translation of key survival and proliferation factors in cancer cells. Consequently, EIF4A1 has emerged as a high-value therapeutic target for small-molecule inhibitors, particularly in treatment-resistant solid tumors and hematological malignancies.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EIF4A1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EIF4A1 Recombinant Protein (WT & Key Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for ATPase and RNA-binding assays. |
View EIF4A1 Products |
| Gene Delivery | EIF4A1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target validation. |
View EIF4A1 Products |
| Benchmark Ab | Anti-EIF4A1 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and IP. |
View EIF4A1 Products |
| Validator | EIF4A1 siRNA Set For knockdown verification and phenotype rescue assays. |
View EIF4A1 Products |
| Related Target A | EIF4E Cap-binding protein cooperating with EIF4A1 in the eIF4F complex. |
View EIF4E Products |
| Related Target B | EIF4G1 Scaffolding protein that recruits EIF4A1 to the translation initiation complex. |
View EIF4G1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| EIF4A1 vs. EIF4A2 Selectivity Screening | Highly purified recombinant EIF4A1 and EIF4A2 proteins available; sequence verified by MS to ensure zero cross-contamination. |
| Drug Resistance Mutation Profiling | Custom mutant proteins (e.g., F183L, H184Y) engineered with precise sequence verification for secondary screening. |
| Lack of Controls | Sequence-defined clinical benchmark antibodies and validated positive controls included in the catalog. |
| False Positives in Small-Molecule Screens | Target-specific siRNA knockdown sets included to confirm on-target cellular phenotypes. |
Live EIF4A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EIF4A1 therapeutics is intensifying, with major players shifting focus from non-selective translation inhibitors to sequence-selective RNA-helix modulating small molecules (e.g., rocaglate derivatives). As first-generation therapies reach the clinic, the next wave of R&D is targeting drug-resistant mutations and exploring combination regimens with MAPK or PI3K/AKT/mTOR pathway inhibitors to bypass adaptive resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Rocaglate/Glue) | eFFECTOR Therapeutics, Kura Oncology | Solid Tumors (NSCLC, CRC, Breast Cancer), Lymphomas | RNA-dependent ATPase/Helicase Assay (Need high-purity WT and mutant EIF4A1) |
| PROTAC / Degraders | Academic Institutes, Biotech Startups | Hematological Malignancies | Ubiquitination & Degradation Kinetics (Need EIF4A1-specific antibodies & siRNA validation) |
| Combination Therapies | Clinical-stage Biopharma | KRAS-mutant and ER+ Her2- Breast Cancers | Synergistic Pathway Screening (Need EIF4E, EIF4G1, and downstream target reagents) |